Preference Study With Elderly Patients Recurrent Ovarian Cancer

• Status: Completed
• Trial end date: 2012-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

Comparison of the patient compliance treosulfan oral vs. intravenous (defined as end of therapy for the patient)

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: North Eastern German Society of Gynaecological Oncology; North Eastern Germany Society of Gynaecologic Oncology
• Treatments: Busulfan; Treosulfan

Criteria

Inclusion Criteria:

• patient with relapsed ovarian cancer

• study therapy of third regime

• measurable or evaluable tumor lesions or progression defined as CA-125 more than >= 100 U/ ml.

• Age >= 70 years

• ECOG 0-2

• written informed consent

Exclusion Criteria:

• Pretreatment with treosulfan

• patient without measurable or evaluable tumor lesions or CA-125 more than >= 100 U/ ml.

• no adequate bone marrow function (leukocyte <= 2,9 x 109/l, platelets <= 100 x 109/ l

• creatinin and bilirubin within >= 1,25 x fold of the reference laboratory´s normal range

• simultaneous radiotherapy